Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. According to the report from World Health Organization in 2019, there were an estimated 229 million cases of malaria worldwide, and the estimated number of annual malaria deaths is around 409 000. Children aged under 5 years are the most vulnerable group affected by malaria. Although antimalaria drugs such as chloroquine, sulfadoxine-pyrimethamine (SP) and artemisinin have been approved as powerful weapons to fight against malaria, resistance to antimalarial medicines is a recurring problem. Protecting the efficacy of antimalarial medicines is critical to malaria control and elimination.

PTI is working with different research organization to put the new treatment of malaria into clinical trials. Our strategy is utilizing the combination of existing treatment with new medicine to mitigate the emerging drug resistance found in the patients around the world.